The best of EcoWatch, right in your inbox. Sign up for our email newsletter!
4 Commonly Prescribed Drugs That May Not Be Safe
They are so common no one thinks twice about them: drug ads that tell you about a disease you might have and a pill that could treat it. Just "ask your doctor," they say, if the pill is right for you.
Until 1997, such direct-to-consumer (DTC) ads did not exist because without a doctor’s recommendation, how could people know if the medication was appropriate or safe? The only thing people knew about drugs and drug risks was from ads they peeked at in medical journals at the doctor's office.
But after the ads started in 1997, the allergy pill Claritin became a household word, along with Xenical, Meridia, Propecia, Paxil, Prozac, Vioxx, Viagra, Singulair, Nasonex, Allegra, Flonase and, of course, Lipitor—and Big Pharma became a Wall Street darling.
Now the American Medical Association (AMA) is taking a second look at DTC advertising. In November 2015, doctors at the AMA's Interim Meeting sought a policy to address one of its biggest problems: the growing proliferation of ads "driving demand for expensive treatments despite the clinical effectiveness of less costly alternatives." Billions are spent advertising expensive new drugs that are not clearly better than existing ones, the AMA said. The Kaiser Family Foundation agreed and said exorbitantly priced drugs—like $1,000-a-pill hepatitis C drugs and recently approved PCSK9-inhibiting cholesterol drugs—are the "public’s top health care priority." The new cholesterol drug will cost an estimated $14,000 a year.
Looting tax dollars and raising health premiums is only one result of DTC advertising. To sell drugs, the ads raise awareness of conditions people never worried about before and probably don't have. Some conditions are so rare the ads appear to be selling the disease itself. How many people, for example, suffer from "Non-24," a condition that mostly affects blind people yet is currently advertised on TV? How many people suffer from "exocrine pancreatic insufficiency" and need to ask their doctor about their "poop" as other ads currently suggest?
Nor are the drugs even clearly safe. Many of the aggressively advertised drugs have risks that have surfaced after their ad campaigns expire (Others like Vioxx, Bextra, Baycol, Trovan, Meridia, Seldane, Hismanal and Darvon were removed from the market altogether).
Here are some heavily advertised drugs that are not necessarily safe.
1. GERD Meds
Few had heard of the condition gastroesophageal reflux disease before DTC advertising. While a small percentage of the population may have GERD, the condition is widely believed to have been pushed to sell proton pump inhibitors (PPI) like Nexium. In many cases "GERD" is really heartburn and can be treated with Tums or Rolaids, critics said.
GERD has made a lot of money. The "Purple Pill," Nexium, made almost $5 billion in the U.S. in one year and the class of PPIs made $13.6 billion, translating into 119 million prescriptions. But safety questions have followed.
In 2012, the U.S. Food and Drug Administration (FDA) warned that PPIs are linked to Clostridium Difficile or C. Dif, a sometimes deadly intestinal infection that is becoming increasingly drug resistant. In 2013, medical literature linked PPIs to fractures, calcium and magnesium deficiencies, community-acquired pneumonia and vitamin B-12 deficiencies. Other research suggests PPIs might cause blood vessels to constrict and cardiovascular risks and this month, research said PPIs may be linked to increased risk for chronic kidney disease.
If DTC advertising was the medium that made Big Pharma a Wall Street darling, statins like Lipitor were the drug class. In 2005 statins earned $18.7 billion in the U.S. and Pfizer’s Lipitor became the best-selling drug in the world.
Patients loved statins because they could ignore diet and exercise advice and still, apparently, reduce heart attack risks; their body would "forgive" the bacon cheeseburger. But not all medical voices agreed. Some wondered why the nation spent approximately $20 billion a year on cholesterol-lowering drugs instead of effective, less dangerous and less expensive lifestyle and diet changes. Others questioned the value of statins themselves.
High cholesterol, which statins treat, is a "relatively weak risk factor for developing atherosclerosis," Barbara Roberts, an associate clinical professor of medicine at the Alpert Medical School of Brown University told me. "Big Pharma has consistently exaggerated the benefits of statins and some physicians used scare tactics so that patients are afraid that if they go off the statins, they will have a heart attack." Though many doctors have "swallowed the Kool-Aid," Dr. Roberts, author of The Truth about Statins, said, "diabetes and smoking are far more potent when it comes to increasing risk."
In 2012, the FDA floated new risks to the entire statin class, adding warnings to their labels about memory impairment, diabetes, liver injury and muscle damage. Memory problems had always been suspected with statins, but after Lipitor's patent ran out, they were confirmed.
Statins were given a big boost by Paul Ridker of Brigham and Women's Hospital in Boston, who presented the results of a study on the statin Crestor, funded by its manufacturer AstraZeneca, in 2009. Even though Ridker was co-inventor of a related patent and stood to profit from sales and study authors listed 131 financial ties to Big Pharma, the media were wowed. Headlines screamed “AstraZeneca's Crestor cuts death, heart attack" and "Crestor study seen changing preventive treatment!" Ka-ching.
But doctors posting online comments in the New England Journal of Medicine were not convinced, especially since the study was stopped early because, AstraZeneca said, of its clearly positive results. "It is well established that RCTs [randomized controlled trials] stopped early overestimate benefits significantly," wrote a physician from Rochester, Minnesota. "It is shocking that this trial was terminated 50 percent through, based on a small absolute benefit, with real questions about long-term risk," a poster from LSU Law Center, read.
During Crestor-mania, few remembered that the FDA's own David Graham had named the drug among the top five most dangerous in Capitol Hill testimony. Public Citizen, the national watchdog group, had petitioned for the drug’s withdrawal and research in the journal Circulation found Crestor "was significantly more likely to be associated with the composite end point of rhabdomyolysis, proteinuria, nephropathy or renal failure" than related drugs.
Vytorin was heavily advertised as treating both genetic and dietary sources of cholesterol and combined the statin drug Zocor with the anti-hyperlipidemic drug Zetia. The problem was, it was marketed before a study confirmed its effectiveness and when the study was published, it found Vytorin had no effect on the buildup of plaque in the arteries. Oops.
Like other expensive and popular drugs, the issue wasn't just that Vytorin did not work any better than a much cheaper drug. Its makers, Merck and Schering-Plough, also admitted "theoretical" safety concerns about liver damage. In 2014, American Journal of Cardiology authors reported an unexpected increase in cancer incidence and mortality in subjects possibly linked to ezetimibe, one of the Vytorin ingredients.
Vytorin demonstrates well the AMA's current concerns about profiteering. The state of New York paid $21 million for Vytorin in two years out of its Medicaid dollars—a likely worthless drug. "Drug companies are on notice that concealing critical information about life-saving prescription drugs, profiting at the expense of patients' health and wasting taxpayer dollars, is simply unacceptable," then New York Attorney Andrew Cuomo, now governor, said.
Vytorin was such a scam, Sen. Chuck Grassley (R-Iowa) asked the General Accounting Office to investigate why the FDA would approve a drug to reduce artery-clogging plaque that didn't reduce artery-clogging plaque. Former Congressmen Bart Stupak (D-MI) and John Dingell (D-MI) asked why Schering-Plough Executive VP Carrie Smith Cox unloaded $28 million in stock when she knew the study failed before the public did.
"Many consumers may not have taken Vytorin had they been aware of the study results," Rep. Stupak said during hearings. He might have added "had they not seen DTC advertising."
YOU MIGHT ALSO LIKE
EcoWatch Daily Newsletter
Tuna auctions are a tourist spectacle in Tokyo. Outside the city's most famous fish market, long queues of visitors hoping for a glimpse of the action begin to form at 5 a.m. The attraction is so popular that last October the Tsukiji fish market, in operation since 1935, moved out from the city center to the district of Toyosu to cope with the crowds.
gmnicholas / E+ / Getty Images
Kristan Porter grew up in a fishing family in the fishing community of Cutler, Maine, where he says all roads lead to one career path: fishing. (Porter's father was the family's lone exception. He suffered from terrible seasickness, and so became a carpenter.) The 49-year-old, who has been working on boats since he was a kid and fishing on his own since 1991, says that the recent warming of Maine's cool coastal waters has yielded unprecedented lobster landings.
The climate crisis is getting costly. Some of the world's largest companies expect to take over one trillion in losses due to climate change. Insurers are increasingly jittery and the world's largest firm has warned that the cost of premiums may soon be unaffordable for most people. Historic flooding has wiped out farmers in the Midwest.
Hawaii's Kilauea volcano could be gearing up for an eruption after a pond of water was discovered inside its summit crater for the first time in recorded history, according to the AP.
'We Should Be Retreating Already From the Coastline,' Scientist Suggests After Finding Warm Waters Below Greenland
By Johnny Wood
The Ganges is a lifeline for the people of India, spiritually and economically. On its journey from the Himalayas to the Bay of Bengal, it supports fishermen, farmers and an abundance of wildlife.
The river and its tributaries touch the lives of roughly 500 million people. But having flowed for millennia, today it is reaching its capacity for human and industrial waste, while simultaneously being drained for agriculture and municipal use.
Here are some of the challenges the river faces.
By Jake Johnson
As a growing number of states move to pass laws that would criminalize pipeline protests and hit demonstrators with years in prison, an audio recording obtained by The Intercept showed a representative of a powerful oil and gas lobbying group bragging about the industry's success in crafting anti-protest legislation behind closed doors.
Speaking during a conference in Washington, DC in June, Derrick Morgan, senior vice president for federal and regulatory affairs at the American Fuel & Petrochemical Manufacturers (AFPM), touted "model legislation" that states across the nation have passed in recent months.
AFPM represents a number of major fossil fuel giants, including Chevron, Koch Industries and ExxonMobil.
"We've seen a lot of success at the state level, particularly starting with Oklahoma in 2017," said Morgan, citing Dakota Access Pipeline protests as the motivation behind the aggressive lobbying effort. "We're up to nine states that have passed laws that are substantially close to the model policy that you have in your packet."
Big Oil is now using its political power to try and criminalize protests of oil & gas infrastructure.— Friends of the Earth (@foe_us) August 19, 2019
"This legislation has potential to punish public participation and mischaracterize advocacy protected by the First Amendment."https://t.co/bmiHjONEhy
The audio recording comes just months after Texas Gov. Greg Abbott signed into law legislation that would punish anti-pipeline demonstrators with up to 10 years in prison, a move environmentalists condemned as a flagrant attack on free expression.
"Big Oil is hijacking our legislative system," Dallas Goldtooth of the Indigenous Environmental Network said after the Texas Senate passed the bill in May.
As The Intercept's Lee Fang reported Monday, the model legislation Morgan cited in his remarks "has been introduced in various forms in 22 states and passed in ... Texas, Louisiana, Oklahoma, Tennessee, Missouri, Indiana, Iowa, South Dakota, and North Dakota."
"The AFPM lobbyist also boasted that the template legislation has enjoyed bipartisan support," according to Fang. "In Louisiana, Democratic Gov. John Bel Edwards signed the version of the bill there, which is being challenged by the Center for Constitutional Rights. Even in Illinois, Morgan noted, 'We almost got that across the finish line in a very Democratic-dominated legislature.' The bill did not pass as it got pushed aside over time constraints at the end of the legislative session."
Many of the state bills restricting the right to protest have been "drafted by companies and passed through groups like ALEC, the secretive group of corporate lobbyists trying to rewrite state laws to benefit corporations over people." @greenpeaceusa https://t.co/ZxpTjWdrwT— Stand Up To ALEC (@StandUpToALEC) May 6, 2019
Reposted with permission from our media associate Common Dreams.